Health Trials

HER2-Positive Solid Tumors

2

Review clinical trials related to HER2-Positive Solid Tumors. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Participants needed: 383
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Iambic Therapeutics, IncUpdated: Jun 4, 2026Locations: 53
Eligibility criteria

Age ≥ 18 years [+7]

Clinically significant cardiac disease [+8]

Read more
Status: Recruiting

A Study of VRN101099 in Patients With HER2-Positive Solid Tumors

This FIH open-label study aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor effect of VRN101099 in patients with HER2-positive solid tumors for whom no standard therapies are available.

Participants needed: 72
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Voronoi, IncUpdated: Aug 28, 2025Locations: 1
Eligibility criteria

Aged ≥ 18 years (patients in Korea must be aged ≥ 19 years). [+7]

Has a confirmed HER2 exon 20 mutation (in the documented NGS test result). [+35]

Read more